PCSK9 inhibition in high-risk patients

Aging (Albany NY). 2019 Dec 11;11(23):10791-10792. doi: 10.18632/aging.102621. Epub 2019 Dec 11.

Authors

Laurien E Zijlstra¹, Simon P Mooijaart^{2

3}, J Wouter Jukema¹

Affiliations

¹ Department of Cardiology Leiden University Medical Center, The Netherlands.
² Department of Gerontology and Geriatrics Leiden University Medical Center, The Netherlands.
³ Institute for Evidence-based Medicine in Old Age (IEMO), Leiden, the Netherlands.

No abstract available

Keywords: PCSK9 inhibiting; cardiovascular disease; lipid-lowering; older patients; plaque burden.

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Anticholesteremic Agents / therapeutic use*
Atherosclerosis / complications
Atherosclerosis / drug therapy*
Atherosclerosis / pathology
Biomarkers
Humans
PCSK9 Inhibitors*

Substances

Anticholesteremic Agents
Biomarkers
PCSK9 Inhibitors
PCSK9 protein, human